LY294002 potentiates the anti-cancer effect of oxaliplatin for gastric cancer via death receptor pathway

Figure 1 LY294002 increased oxaliplatin-induced cell proliferation and apoptosis in gastric cancer cells. MKN45 and AGS cells were treated with various doses of oxaliplatin (0-20 μmol/L) for 24 h with or without LY294002 pretreatment (25 μmol/L). A, C: Cell growth inhibitory rates were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay; B, D: Apoptosis of cells was investigated by flow cytometry. LY294002 significantly increased oxaliplatin-induced growth inhibition and apoptosis. ^aP < 0.05, ^bP < 0.01 vs oxaliplatin alone.